Skip header and navigation

1 records – page 1 of 1.

Patient-specific academic detailing for smoking cessation: feasibility study.

https://arctichealth.org/en/permalink/ahliterature256860
Source
Can Fam Physician. 2014 Jan;60(1):e16-23
Publication Type
Article
Date
Jan-2014
Author
Margaret Jin
Antony Gagnon
Mitchell Levine
Lehana Thabane
Christine Rodriguez
Lisa Dolovich
Author Affiliation
Hamilton Family Health Team, Pharmacy, 10 George St, 3rd Floor, Hamilton, ON L8P 1C8. margaret.jin@hamiltonfht.ca.
Source
Can Fam Physician. 2014 Jan;60(1):e16-23
Date
Jan-2014
Language
English
Publication Type
Article
Keywords
Cohort Studies
Education, Medical, Continuing - methods
Feasibility Studies
Female
Humans
Male
Models, Educational
Nurse Practitioners - education
Ontario
Pharmacists
Physicians, Primary Care - education
Primary Health Care - methods
Smoking Cessation
Tobacco Use Cessation Products
Abstract
To describe and to determine the feasibility of a patient-specific academic detailing (PAD) smoking cessation (SC) program in a primary care setting.
Descriptive cohort feasibility study.
Hamilton, Ont.
Pharmacists, physicians, nurse practitioners, and their patients.
Integrated pharmacists received basic academic detailing training and education on SC and then delivered PAD to prescribers using structured verbal education and written materials. Data were collected using structured forms.
Five main feasibility criteria were generated based on Canadian academic detailing programs: PAD coordinator time to train pharmacists less than 40 hours; median time of SC education per pharmacist less than 20 hours; median time per PAD session less than 60 minutes for initial visit; percentage of prescribers receiving PAD within 3 months greater than 50%; and number of new SC referrals to pharmacists at 6 months more than 10 patients per 1.0 full-time equivalent (FTE) pharmacist (total of approximately 30 patients).
Eight pharmacists (5.8 FTE) received basic academic detailing training and education on SC PAD. Forty-eight physicians and 9 nurse practitioners consented to participate in the study. The mean PAD coordinator training time was 29.1 hours. The median time for SC education was 3.1 hours. The median times for PAD sessions were 15 and 25 minutes for an initial visit and follow-up visit, respectively. The numbers of prescribers who had received PAD at 3 and 6 months were 50 of 64 (78.1%) and 57 of 64 (89.1%), respectively. The numbers of new SC referrals at 3 and 6 months were 11 patients per FTE pharmacist (total of 66 patients) and 34 patients per FTE pharmacist (total of 200 patients), respectively.
This study met the predetermined feasibility criteria with respect to the management, resources, process, and scientific components. Further study is warranted to determine whether PAD is more effective than conventional academic detailing.
Notes
Cites: Br J Clin Pharmacol. 2000 Feb;49(2):168-7310671912
Cites: BMJ. 2001 Mar 17;322(7287):654-711250852
Cites: Prim Care. 2007 Mar;34(1):117-3517481990
Cites: Med J Aust. 2007 Jul 2;187(1):23-3017605699
Cites: Cochrane Database Syst Rev. 2007;(4):CD00040917943742
Cites: Pharmacotherapy. 2007 Nov;27(11):1550-717963463
Cites: BMC Med Educ. 2007;7:3617935614
Cites: Cochrane Database Syst Rev. 2008;(2):CD00016518425860
Cites: Clin Pharmacol Ther. 2008 Jun;83(6):913-718388882
Cites: BMC Med Res Methodol. 2010;10:120053272
Cites: Cochrane Database Syst Rev. 2010;(3):CD00518220238338
Cites: Health Promot Pract. 2012 Sep;13(5):657-6522496459
Cites: J Antimicrob Chemother. 2004 Sep;54(3):661-7215282232
Cites: Ann Intern Med. 2001 Mar 20;134(6):479-8611255524
Cites: Arch Intern Med. 2001 Aug 13-27;161(15):1897-90211493132
Cites: Med Care. 2001 Aug;39(8 Suppl 2):II2-4511583120
Cites: Br J Gen Pract. 2002 Apr;52(477):290-511942445
Cites: Nicotine Tob Res. 2002;4 Suppl 1:S38-4411945218
Cites: Clin Infect Dis. 2002 Jul 15;35(2):113-2512087516
Cites: Br Dent J. 2006 Aug 26;201(4):217-22; discussion 21616902573
Cites: Prev Med. 2002 Dec;35(6):572-8312460525
Cites: Prev Med. 2003 Feb;36(2):185-9612590994
Cites: JAMA. 2004 Apr 7;291(13):1587-9515069046
Cites: N Engl J Med. 1983 Jun 16;308(24):1457-636406886
Cites: Br J Clin Pharmacol. 1992 Jan;33(1):69-731540493
Cites: J Cancer Educ. 1993 Winter;8(4):273-808186079
Cites: Eur J Clin Pharmacol. 1994;46(6):501-57995315
Cites: Aust J Public Health. 1995 Apr;19(2):142-87786939
Cites: J Am Geriatr Soc. 1998 Jan;46(1):77-829434669
Cites: Med J Aust. 1999 May 17;170(10):471-410376022
Cites: WMJ. 2005 May;104(4):32-616117231
Cites: Eur J Gen Pract. 2005 Jun;11(2):59-6316392778
Cites: Fam Pract. 2006 Feb;23(1):60-416332945
Cites: BMC Med Inform Decis Mak. 2006;6:1416533386
Cites: Arch Intern Med. 2006 Jul 10;166(13):1345-616831998
Cites: Arch Intern Med. 2006 Jul 10;166(13):1374-916832002
Cites: Arch Intern Med. 2010 May 24;170(10):851-820498411
Cites: Cochrane Database Syst Rev. 2010;(7):CD00033620614422
Cites: Am J Prev Med. 2012 Jan;42(1):21-822176842
PubMed ID
24452574 View in PubMed
Less detail